SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
18.98
-0.04 (-0.21%)
Apr 15, 2025, 2:59 PM CET
168.84%
Market Cap 934.11M
Revenue (ttm) n/a
Net Income (ttm) -82.40M
Shares Out 49.01M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 83,879
Average Volume 174,531
Open 19.04
Previous Close 19.02
Day's Range 18.82 - 19.42
52-Week Range 6.55 - 20.60
Beta 1.10
RSI 62.66
Earnings Date Apr 10, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.